TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00796666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan and Sildenafil
Description: Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
Study: NCT00800566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Clofarabine
Description: The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
Study: NCT02171507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study: NCT02653326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Monitors
Description: After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depression Screening
Description: Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression Screening
Description: Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Comorbidities
Description: Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Comorbidities
Description: Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
Study: NCT01028105

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative MRSA screening
Description: MRSA preoperative screening and post operative infection rate, 30 days post operative
Study: NCT03041571

Intervention type: BEHAVIORAL
Intervention: Patient Provider Orientation Scale
Description: Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.

Intervention type: BEHAVIORAL
Intervention: Patient Provider Orientation Scale
Description: Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.

Intervention type: BEHAVIORAL
Intervention: Interview performed by MHP student
Description: The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system.

Intervention type: BEHAVIORAL
Intervention: Interview performed by MHP student
Description: The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system.
Study: NCT02255916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: live sound-bed music intervention
Study: NCT00802516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stanol ester
Description: enriched margarine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sterol ester
Description: enriched margarine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: placebo margarine
Study: NCT02386046

Intervention type: OTHER
Intervention: Pulse oxymeter measurements
Description: Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age

Intervention type: OTHER
Intervention: Pulse oxymeter measurements
Description: Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age

Intervention type: OTHER
Intervention: Pulse oxymeter measurements
Description: Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
Study: NCT00902681

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
Study: NCT02374164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat XR capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat XR capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat XR capsules
Study: NCT00255190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
Study: NCT01990521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MS3TMRI / TRUS Guided Biopsy
Description: Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS3TMRI / TRUS Guided Biopsy
Description: Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished).
Study: NCT03074708

Intervention type: OTHER
Group type: OTHER
Intervention: 3D visualization and 3D printing
Description: From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
Study: NCT03008161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT088
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT088
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT088
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT088
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02638766

Intervention type: DRUG
Group type: OTHER
Intervention: regorafenib
Description: Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
Study: NCT03287817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO3
Description: Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of anti-PD1 antibody (pembrolizumab).
Study: NCT01811888

Intervention type: BEHAVIORAL
Intervention: Quantitative sensory testing (QST)
Study: NCT03890068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: 48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
Study: NCT02767271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1%
Description: Luliconazole cream will be applied topically per schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1%
Description: Luliconazole cream will be applied topically per schedule specified in the arms.
Study: NCT02626585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postrhinoplasty taping
Description: Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postrhinoplasty taping
Description: Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
Study: NCT00429559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamptin
Description: 1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression
Study: NCT02053012

Intervention type: DEVICE
Intervention: PVT-192
Description: PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
Study: NCT00657046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: Capsules containing 200 mg droxidopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: Capsules containing 200 mg droxidopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules with mannitol substituted for droxidopa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with mannitol substituted for droxidopa
Study: NCT02931019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Study: NCT01303939

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: magnetic resonance imaging (MRI) of the brain
Description: High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: magnetic resonance imaging (MRI) of the brain
Description: High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
Study: NCT04197349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD1910
Description: Single Dose IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD1910
Description: Single Dose IV infusion
Study: NCT02830360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrythmic Drug Therapy
Description: Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
Study: NCT04197349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Single dose subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD1910
Description: Single dose subcutaneous injection
Study: NCT00286442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and metformin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and metformin
Description: Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
Study: NCT00961155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyklezonid
Description: 160 mcg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: 5 or 10 mg according to age once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: fluticasone placebo twice daily, montelukast placebo once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol 12 mcg twice daily
Description: formoterol 12 mcg twice daily will be given to children for 3 months
Study: NCT02982395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoxel®M
Description: Intravesical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C
Description: Intravesical
Study: NCT00670839

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GenHevac-B
Description: 1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenHevac-B
Description: 2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
Study: NCT02265627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Study: NCT04019223

Intervention type: DIAGNOSTIC_TEST
Intervention: anti-tissue transglutaminase group
Description: Determination of anti-tissue transglutaminase IgA antibodies serum level.

Intervention type: DIAGNOSTIC_TEST
Intervention: anti-tissue transglutaminase group
Description: Determination of anti-tissue transglutaminase IgA antibodies serum level.

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy group
Description: Intestinal biopsy for histopathology study the jejunal histopathological

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy group
Description: Intestinal biopsy for histopathology study the jejunal histopathological
Study: NCT02961543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.
Study: NCT01488877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 3 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: up to 10 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: up to 30 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: spironolactone 25 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily
Study: NCT00377442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 80mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 80mg po
Study: NCT00752947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
Study: NCT00955253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 2mg oral guanfacine (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 2mg oral guanfacine (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo